CCR5 Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients.

Trial Profile

CCR5 Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Mar 2013

At a glance

  • Drugs Maraviroc (Primary) ; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate
  • Indications HIV-1 infections
  • Focus Adverse reactions; Biomarker; Pharmacogenomic
  • Acronyms CADIRIS
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Mar 2013 Status changed from active, no longer recruiting to completed.
    • 06 Mar 2013 Results presented at the 20th Conference on Retroviruses and Opportunistic Infections.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top